Demant CEO on implant recall and sales halt: "This is very serious"

A serious setback for Demant's surgical division Oticon Medical, as the company has had to recall numerous implant devices due to a performance issue, in addition to halting the sales of said device, says President and CEO at Demant Søren Nielsen, who has launched a thorough investigation to locate the root cause.

Photo: Kenneth Lysbjerg Koustrup/Jyllands-Posten/Ritzau Scanpix

Hearing aid manufacturer Demant prepares for another economic blow. In 2019, the company was hit by a hacking attack that laid its operations low for several weeks. Then, the company was sent to its knees when the market froze over because of the Covid-19 pandemic.

After a functional error was discovered in a produt, Demant's subsidiary Oticon Medical announced on Thursday that it is withdrawing almost 4,000 non-implanted devices of its Neuro Zti product type. Additionally, the sales of said device have been stopped. Faulty devices will be removed from the 28 patients who have already had the cochlear device implanted.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Lundbeck chairman demands change: "We can't live with this"

Years of work developing new treatments at Lundbeck has so far come to nothing. This has led chairman Lars Rasmusssen to demand visible results, even though CEO Deborah Dunsire has essentially had to restart development work since she joined the firm in 2018.

Eli Lilly upgrades earnings per share guidance

On Tuesday, US-based pharmaceutical firm Eli Lilly has updated elements of its 2021 financial guidance pertaining to earnings per share (non-GAAP), now expecting USD 7.95-8.05 compared to the previous USD 7.8-8.

Further reading

Related articles

Trial banner

Latest news

See all jobs